WO2024008655 - PHARMACEUTICAL COMPOSITION AND METHOD FOR ENHANCING SOLUBILITY OF POORLY SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS
National phase entry:
Publication Number
WO/2024/008655
Publication Date
11.01.2024
International Application No.
PCT/EP2023/068253
International Filing Date
03.07.2023
Title **
[English]
PHARMACEUTICAL COMPOSITION AND METHOD FOR ENHANCING SOLUBILITY OF POORLY SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS
[French]
COMPOSITION PHARMACEUTIQUE ET PROCÉDÉ POUR AMÉLIORER LA SOLUBILITÉ D'INGRÉDIENTS PHARMACEUTIQUES ACTIFS FAIBLEMENT SOLUBLES
Applicants **
MERCK PATENT GMBH
Inventors
KIPPING, Thomas
LINDH, Jonas
QUODBACH, Julian
Priority Data
22183236.3
06.07.2022
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2016 | |
| EPO | Filing, Examination, Granting | 8126 | |
| Japan | Filing, Examination, Granting | 2181 | |
| South Korea | Filing, Examination, Granting | 2020 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
19,083
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure generally relates to the use of poloxamer in additive manufacturing technologies and techniques. More specifically, the present disclosure relates to the use of poloxamer in a selective laser sintering (SLS) method to additively manufacture an object, in particular a pharmaceutical dosage form.[French]
La présente invention concerne de manière générale l'utilisation de poloxamère dans des technologies et des techniques de fabrication additive. Plus spécifiquement, la présente invention concerne l'utilisation de poloxamère dans un procédé de frittage laser sélectif (SLS) pour fabriquer de manière additive un objet, en particulier une forme posologique pharmaceutique.